Notably, similar patterns of dysregulation are observed in inflammation-associated cancers, such as pancreatic ductal adenocarcinoma, gastrointestinal malignancies, and primary liver cancer, raising the possibility that REG3A could serve as a diagnostic or prognostic biomarker. Here, REG3A is linked to pancreatic ductal adenocarcinoma.